Aytu BioPharma(AYTU) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results Net income of $1.5 million Adjusted EBITDA1 of $1.9 million ADHD Portfolio net revenue up 1% to $15.3 million Pediatric Portfolio net revenue up 54% sequentially $20.1 million cash balance at September 30, 2024 Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flow Ryan Selhorn promoted to Chief Financial Of ...